LivQ-box Measurements for Detecting Liver Inflammation in Fatty Liver Disease
Studies how a LivQ-box device measures liver inflammation in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: LivQ-box® Parameters in the Diagnosis of Liver Inflammation
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-alcoholic fatty liver disease (NAFLD) who have had a liver tissue exam and an iLivTouch scan close together in time.
- Age
- Over 18 years old
- Sex
- All sexes can join
- Disease stage
- Diagnosed non-alcoholic fatty liver disease (NAFLD), as defined in the American Association for the Study of Liver Diseases practice guidance
- Biomarker or test result
- An iLivTouch examination within ± 14 days of the liver pathology examination
Main reasons for not taking part
- Other liver diseases, such as viral hepatitis, drug-induced liver injury or autoimmune liver disease
- History of excessive alcohol use (more than 140g of ethanol per week for men, more than 70g per week for women)
Read by machine on 12 November 2026.
Where in China
- Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua UniversityBeijing, ChinaContact: Lai WeiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Wuxi Hisky Medical Technology Co Ltd
- Trial code
- NCT06802731
- Record updated
- 31 January 2025
- Original description
To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.Read full original descriptionShow less
A Multicenter Study on the Application of LivQ-box® Parameters in the Diagnosis of Liver Inflammation in Patients with Non-alcoholic Fatty Liver Disease
To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.
Inclusion: Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases; Age over 18 years old, gender not limited; Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease); Perform iLivTouch examination within ± 14 days of liver pathology examination; No history of excessive alcohol consumption (converted to ethanol:<140g/week for males,<70g/week for females).